OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Episode 55: Developing a Maternal RSV Vaccine
Christen Harm
Christen Harm is Pharmaceutical Executive's Associate Editor. Email her at charm@mmhgroup.com
Elaine Quilici
Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com
Pharmaceutical Executive
Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.
Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Pharmaceutical Executive Magazine
·
Episode 55: Developing a Maternal RSV Vaccine
Related Content:
Editorial Podcasts